Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Pre-Close Trading Update

14 May 2015 07:00

RNS Number : 1134N
Ideagen PLC
14 May 2015
 

 

 

Ideagen plc

("Ideagen" or the "Group'')

 

Pre-Close Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, announces a trading update for the year ended 30 April 2015.

 

Trading for the year to 30 April 2015 was robust and in line with expectations with both continued organic growth and contributions from EIBS and Gael. The results will therefore show the Group's sixth consecutive year of revenue and EBITDA* growth, with revenue expected to be up 59 per cent. to approximately £14.3 million and adjusted EBITDA expected to be up by 42 per cent. to approximately £4 million. This will lead to a significant increase in adjusted EPS** which continues to be an important financial metric for the Group and has averaged growth of 24 per cent. per annum since 2012.

 

Cash at 30 April was £5.25m and with no debt our strong balance sheet provides the Group with the capacity to pursue further strategic opportunities in the current financial year.

 

*Earnings before interest, tax, depreciation, amortisation, share based payments, acquisition costs and exceptional items.

** Adjusted fully diluted earnings per share,

 

Performance and Integration of Gael

 

The acquisition of Gael has transformed the Group and has made a strong and positive contribution both financially and in terms of product capability. Integration is well underway and a number of existing Ideagen customers have upgraded their existing installations to take advantage of the enhanced proposition that the Group can now offer. Having successfully executed our immediate objectives we can now accelerate the integration of Gael into the Group. To enable this Ashley Marron, Chief Executive of Gael has been appointed Group Chief Operating Officer with responsibility for all of Ideagen's Product Strategy and Development and Customer Services.

 

Outlook

 

The Group has significant contracted work in progress, a growing recurring revenue base and a strong pipeline of new business. We have experienced robust growth within our Commercial Markets such as Manufacturing, Life Sciences, Aviation and Banking which, we expect to continue. We are also seeing renewed momentum within a number of sales opportunities at NHS Hospital Trusts, which had slowed prior to the election. The Board is therefore confident that the Group will continue to meet its growth objectives for this financial year and beyond.

 

David Hornsby, Chief Executive, commented: "The Group has once again met market expectations, demonstrating the strength of our business model and products and the talent and dedication of our employees. I am delighted with the contribution from our newly acquired businesses, Gael and EIBS, and look forward to an exciting year ahead

 

 

 

Enquiries:

Ideagen Plc

Tel: 01629 699100

David Hornsby (Chief Executive)

 

Graeme Spenceley (Finance Director)

 

 

 

finnCap (Nominated Adviser and Broker)

Tel: 020 7220 0500

Stuart Andrews, James Thompson (Corporate Finance)

 

Stephen Norcross (Corporate Broking)

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQXLFFEEFBBBE
Date   Source Headline
10th Aug 201711:45 amRNSDirector Dealing
28th Jul 20174:19 pmRNSDirector Dealing
18th Jul 20177:00 amRNSFinal Results
12th Jun 20178:45 amRNSHolding(s) in Company
18th May 20173:19 pmRNSExercise of Options and Total Voting Rights
17th May 20177:00 amRNSPre-Close Trading Update
11th May 20172:21 pmRNSHolding(s) in Company
31st Mar 20171:10 pmRNSDirector/PDMR Shareholding
30th Mar 201711:48 amRNSHolding(s) in Company
30th Mar 20177:00 amRNSNew Aviation SaaS contracts worth £1.8m
28th Mar 20179:16 amRNSHolding(s) in Company
27th Mar 20176:05 pmRNSHolding(s) in Company
23rd Mar 201710:49 amRNSDirectors' Dealing & Total Voting Rights
23rd Mar 20177:00 amRNSAcquisition and Placing to raise £10m
1st Mar 201711:47 amRNSExercise of Options and Total Voting Rights
1st Mar 20177:00 amRNSHolding(s) in Company
24th Feb 20172:28 pmRNSExercise of Options and Total Voting Rights
24th Feb 201712:20 pmRNSHolding(s) in Company
21st Feb 20177:00 amRNSExercise of Options and Total Voting Rights
1st Feb 201711:44 amRNSHolding(s) in Company
26th Jan 20178:29 amRNSDividend Timetable
24th Jan 20177:01 amRNSDirectorate Changes
24th Jan 20177:00 amRNSInterim Results
9th Dec 20167:00 amRNSAcquisition of IPI Solutions Ltd
7th Dec 20162:14 pmRNSHolding(s) in Company
28th Nov 20164:55 pmRNSHolding(s) in Company
24th Nov 20167:00 amRNSHolding(s) in Company
16th Nov 201611:37 amRNSHolding(s) in Company
7th Nov 20167:00 amRNSTrading Update
2nd Nov 20167:00 amRNSExercise of Options and Total Voting Rights
28th Oct 20161:26 pmRNSResult of AGM
13th Oct 20167:00 amRNSNew Contract Wins worth £1.2m
11th Oct 20167:00 amRNSExercise of Options and Total Voting Rights
6th Oct 20167:00 amRNSNotice of AGM
6th Sep 20167:00 amRNSAcquisition of Logen Ltd.
1st Sep 20167:00 amRNSExercise of Options and Total Voting Rights
12th Aug 20167:00 amRNSExercise of Options and Total Voting Rights
8th Aug 20167:00 amRNSAcquisition of Covalent Software Ltd
29th Jul 20167:00 amRNSExercise of Options and Total Voting Rights
19th Jul 20163:28 pmRNSDividend Timetable
19th Jul 20167:00 amRNSFinal Results
12th Jul 20167:00 amRNSNotice of Results
5th Jul 20167:00 amRNSHolding(s) in Company
29th Jun 20161:56 pmRNSHolding(s) in Company
18th May 20167:00 amRNSPre-Close Trading Update
5th May 20167:00 amRNSExercise of Options and Total Voting Rights
29th Apr 20167:00 amRNSNew contract wins in life science sector
29th Mar 20167:00 amRNSExercise of Options and Total Voting Rights
18th Mar 20167:00 amRNSRe £4.9m Contract and Trading Update
29th Jan 20168:33 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.